Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mimi Mai"'
Autor:
Elizabeth L. Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Chrysis Michaloglou, Adina Hughes, Mimi Mai, Matthew King, Anisha Solanki, Lukasz Magiera, Ricardo Miragaia, Gozde Kar, Nathan Standifer, Michael Surace, Shaan Gill, Alison Peter, Sara Talbot, Sehmus Tohumeken, Henderson Fryer, Ali Mostafa, Kathy Mulgrew, Carolyn Lam, Scott Hoffmann, Daniel Sutton, Larissa Carnevalli, Fernando J. Calero-Nieto, Gemma N. Jones, Andrew J. Pierce, Zena Wilson, David Campbell, Lynet Nyoni, Carla P. Martins, Tamara Baker, Gilberto Serrano de Almeida, Zainab Ramlaoui, Abdel Bidar, Benjamin Phillips, Joseph Boland, Sonia Iyer, J. Carl Barrett, Arsene-Bienvenu Loembé, Serge Y. Fuchs, Umamaheswar Duvvuri, Pei-Jen Lou, Melonie A. Nance, Carlos Alberto Gomez Roca, Elaine Cadogan, Susan E. Critichlow, Steven Fawell, Mark Cobbold, Emma Dean, Viia Valge-Archer, Alan Lau, Dmitry I. Gabrilovich, Simon T. Barry
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract The Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy. Here we
Externí odkaz:
https://doaj.org/article/189773f2417346dcbdf8b6281d57effa
Autor:
Dmitry Gabrilovich, Simon Barry, Mark Cobbold, Sehmus Tohumeken, Kathy Mulgrew, Marta Milo, Emilio Sanseviero, Devon Taylor, Mimi Mai, Ali Mostafa, Serge Fuchs
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/cf813e0a4a104ae4b72e78732ed53681
Autor:
Abeer Shibli, Martha Glenn, Christopher A. Lazarski, Fahmida Hoq, Boyu Hu, Mimi Mai, Melanie Grant, Maja Stanojevic, Stephanie Ann Bien, Richard F. Ambinder, Catherine M. Bollard, Hema Dave, Reuven J. Schore, Keri Toner, Philp Maglo, Madeline Terpilowski, Patrick J. Hanley
Publikováno v:
Blood Advances
Key Points Multi–TAA-Ts can be generated from patients who have failed prior chemo-immunotherapies for HL.TAA-Ts are safe when given alone and persist long term in responders, and nivolumab increases persistence of TAA-Ts in vivo.
Visual Abstr
Visual Abstr
Autor:
Terzah M. Horton, Frank G. Keller, Gaye Jenkins, Mimi Mai, Qinglin Pei, Catherine M. Bollard, Hema Dave, Anushree Datar, Yue Wu, Sharon M. Castellino
Publikováno v:
Blood. 136:41-42
Introduction: The role of the immune system and the microenvironment in Hodgkin Lymphoma (HL) has been well established. However, little is known about the effects of treatment on the immune cells in the peripheral blood or the frequency of tumor spe
Autor:
Abeer Shibli, Melanie Grant, Richard F. Ambinder, Morgan Galligan, Keri Toner, Catherine M. Bollard, Hema Dave, Nan Zhang, Jay Tanna, Martha Glenn, Christopher A. Lazarski, Patrick J. Hanley, Madeline Terpilowski, Mimi Mai, Maja Stanojevic, Philip Y Maglo
Publikováno v:
Blood. 136:18-18
Background: Hodgkin Lymphoma (HL) Reed Sternberg cells express tumor associated antigens (TAA) that are potential targets for cellular therapies. We recently demonstrated that TAA specific T cells (TAA-T) targeting WT1, PRAME and Survivin were safe a